Please assess the completion status of the following clinical trial:

Trial Title: Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to give informed consent~* Male or female patient whose age is \> 18 years of age~* Histological documented Stage IV malignant melanoma (American Joint Committee on Cancer (AJCC) sixth edition)~* Pathology report from tumor specimen verifying melanoma diagnosis~* Free of infection~* Hemoglobin\> 9.0 grams per deciliter (gm/dL), White Blood Cells (WBC) \>3000/ cubic millimeters (mm3), platelets\> 100,000mm3~* Liver function test that are less than 2 times the upper limit of normal of the reference range for the testing laboratory~* Adequate cardiac function-any evidence of ischemic heart disease demonstrated by history, physical, or EKG will require referral to a cardiologist for evaluation and clearance prior to protocol therapy~* No immunotherapy within the past 3 months~* A minimum of 4 doses of lot-released, autologus Melaxin (1.0 million dendritomas)~Exclusion Criteria:~* Other malignancies in the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix~* Has received any immunosuppressive agent within 30 days prior to treat~* Creatinine\> 2.5 milligrams per deciliter (mg/dL) or currently on dialysis~* Positive serum pregnancy test, breast-feeding,or planning to conceive or father or father a child in the period surrounding the study as described in the informed consent.~* Women of childbearing potential who cannot follow the directions for birth control~* Eastern Cooperative Oncology Group (ECOG) performance status greater than 3~* Positive Rdonr panel (Human Immunodeficiency virus (HIV) 1, 2; Human T-lymphotropic virus (HTLV-1,2); Hepatitis B and C)~* History of a seizure disorder~* Brain metastases that have progressed within the last 6 months~* No measurable disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melaxin and BCG (Type: EXPERIMENTAL): Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration

Based on this trial design, predict the completion outcome and termination type (if applicable).